title: Emibetuzumab
text: # Emibetuzumab
  
  Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC
  
  This drug was developed by Eli Lilly & Company.
  
  